Inventprise is leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.
Inventprise platform technologies are designed to enable high valent vaccines to induce broad, robust, and durable protection against pathogenic strains of infectious diseases.
In addition to its lead candidate, the 25-valent pneumococcal conjugate vaccine, Inventprise has a robust pipeline of investigational vaccines including candidates to prevent group B streptococcus (GBS), Shigella and Klebsiella.
Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally.
Our mission is to empower people to live healthy lives by inventing better vaccines.
We leverage the best of vaccine technology, science and manufacturing to prevent infectious disease
Our Focus is on Science
Together with our community of collaborators, Inventprise engages in cutting-edge research bringing incisive scientific insights and novel products to global populations in need of important, life saving vaccines.
Our efforts have led to over fifty patents, many on proprietary approaches and methods in the development of highly immunogenic vaccines.
With multiple partners and collaborations, and a large portfolio of vaccine candidates, our aim is to remain true to our science, continue to innovate and deliver better vaccines to the world.